Cargando…

Cyclin D1 expression in KRAS mutant non-small cell lung cancer—old wine into new skins

Detalles Bibliográficos
Autores principales:	Goh, Kah Yee, Lim, Wan-Teck
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815367/ https://www.ncbi.nlm.nih.gov/pubmed/33489791 http://dx.doi.org/10.21037/tlcr-20-639

Ejemplares similares

Bosutinib inhibits migration and invasion via ack1 in kras mutant non-small cell lung cancer
por: Tan, Daniel SW, et al.
Publicado: (2014)

Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth
por: Bouclier, Celine, et al.
Publicado: (2020)

Old Friends, Old Wine, and Old COPD Classification Are Best
por: Rhee, Chin Kook
Publicado: (2018)

Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer
por: Wang, Yadong, et al.
Publicado: (2022)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Realities of KRAS-mutated non-small cell lung cancer
por: Min, Young Joo
Publicado: (2017)

Osteoarthritis, an old wine in a new bottle!
por: Muthu, Sathish
Publicado: (2023)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Distinct metabolic preference of atypical KRAS mutant
por: Cheong, Heesun
Publicado: (2020)

Mutant KRAS Exosomes Influence the Metabolic State of the Colon Microenvironment
por: Preet, Ranjan, et al.
Publicado: (2018)

Divide and conquer: towards isoform-specific diagnosis and therapy of KRAS-mutant lung cancer
por: Allemann, Anna T., et al.
Publicado: (2023)

Mycobacterium and sarcoidosis: Old wine in a new bottle
por: Bandyopadhyay, Debabrata, et al.
Publicado: (2014)

Ticagrelor in Stroke Prevention New Wine in an Old Bottle?
por: Padma Srivastava, M. V., et al.
Publicado: (2022)

Small molecular inhibitors for KRAS-mutant cancers
por: Wu, Xuan, et al.
Publicado: (2023)

Expression and role of EGFR, cyclin D1 and KRAS in laryngocarcinoma tissues
por: Lin, Xinsheng, et al.
Publicado: (2019)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Current therapy of KRAS-mutant lung cancer
por: Ghimessy, Aron, et al.
Publicado: (2020)

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells
por: Brunelli, Laura, et al.
Publicado: (2014)

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
por: Uras, Iris Z., et al.
Publicado: (2020)

KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
por: Xie, Mingying, et al.
Publicado: (2021)

Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer
por: Li, Yunchang, et al.
Publicado: (2022)

Developing qualitative methods - or “same old wine in a new bottle”
por: Berterö, Carina
Publicado: (2015)

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
por: Adderley, Helen, et al.
Publicado: (2019)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

Acquired palbociclib resistance in KRAS-mutant lung cancer
por: Sherr, Charles J.
Publicado: (2018)

Transposable element RNA dysregulation in mutant KRAS(G12C) 3D lung cancer spheroids
por: Carrillo, David, et al.
Publicado: (2023)

Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival
por: Amanam, Idoroenyi, et al.
Publicado: (2020)

SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer
por: Wang, Xiaowen, et al.
Publicado: (2021)

Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer
por: Maroni, Giorgia, et al.
Publicado: (2021)

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
por: Désage, Anne-Laure, et al.
Publicado: (2022)

KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges
por: Ceddia, Serena, et al.
Publicado: (2022)

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
por: Kharbanda, Akriti, et al.
Publicado: (2014)

Kinase independent oncogenic cyclin D1
por: Casimiro, Mathew C., et al.
Publicado: (2015)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC
por: Goh, Kah Yee, et al.
Publicado: (2023)

Cell phone based ECG monitoring: Old wine in new bottle, or something better?
por: Jaswal, Aparna, et al.
Publicado: (2020)

Matrisomal genes in squamous cell carcinoma of head and neck influence tumor cell motility and response to cetuximab treatment
por: Goh, Kah Yee, et al.
Publicado: (2022)

A combinatorial strategy for treating KRAS mutant lung cancer
por: Manchado, Eusebio, et al.
Publicado: (2016)

Targeting KRAS mutant lung cancer: light at the end of the tunnel
por: Drosten, Matthias, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8r05kbncs6cnporftra947qmvr